Epidermal growth factor receptor (EGFR) participates in a variety of cancer-related signal transduction pathways, and its tyrosine kinase activity plays a key role in mediating these processes.[34] Gefitinib and erlotinib are EGFR tyrosine kinase inhibitors.[31] Our results suggest that AIM1L may play a critical role in resistance to EGFR-targeted treatment in ESCC patients. This evidence concerns the gene CRYBG2 and cancer.